In recent years, the study of anticancer bioactive compounds from marine sources has
received wide interest. Contextually, world regulatory authorities have approved several …

Triple negative breast cancer (TNBC) is characterized by distinctive biological features that
confer an aggressive clinical behavior. In TNBC patients, the absence of well-defined driver …

Eribulin mesylate (EM) was recently approved for metastatic breast cancer (MBC)
chemotherapy (CT) in late lines by the FDA, with debated results in second line. We …

Introduction Eribulin was approved in the United States (US) in 2010 for patients with
metastatic breast cancer (MBC) who previously received at least two chemotherapeutic …

Eribulin is a novel microtubule inhibitor with mitotic and nonmitotic mechanisms of action.
Both pooled and subgroup analyses from large-scale Phase III clinical trials demonstrated …

Background: Patients with Triple-negative breast cancer (TNBC) face a poor prognosis and
limited therapeutic options. Current data on eribulin usage to treat TNBC is scarce …

Purpose We hypothesized that eribulin combined with cyclophosphamide (EC) would be an
effective combination with tolerable toxicity for the treatment of advanced breast cancer …

Background Eribulin mesylate (eribulin) is indicated for patients with metastatic breast
cancer (MBC) who have previously received at least two chemotherapies in the US and for …

Introduction: Large and consistent evidence supports the use of eribulin mesylate in clinical
practice in third or later line treatment of metastatic triple negative breast cancer (mTNBC) …

Purpose Eribulin mesylate (EM) is a non-taxane microtubule inhibitor approved for use in
patients with metastatic breast cancer. With this pooled analysis of retrospective studies, we …